SHAREHOLDERS' EQUITY (Details Textual) $ / shares in Units, $ in Thousands					1 Months Ended						3 Months Ended	6 Months Ended		12 Months Ended
	Feb. 10, 2020	Jun. 12, 2019 $ / shares shares	Jun. 06, 2019 $ / shares shares	Jun. 05, 2019 $ / shares shares	Apr. 30, 2019 $ / shares shares	Mar. 27, 2019	Feb. 28, 2019 USD ($) $ / shares shares	Nov. 30, 2018	May 31, 2018	Mar. 06, 2018 USD ($) shares	Jun. 30, 2020 USD ($) shares	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2019 $ / shares	Dec. 31, 2015 $ / shares	Dec. 31, 2019 USD ($) shares	Jun. 12, 2019 ₪ / shares shares	Dec. 28, 2016 USD ($)
Shareholders' Equity (Textual)
Expected term of shares													6 years 1 month 9 days
Description of underwriting agreement	The Company closed a “best efforts” public offering whereby the Company issued an aggregate of 5,600,000 of common units and pre-funded units at a public offering price of $1.25 per common unit and $1.249 per pre-funded unit. As part of the public offering, the Company entered into a securities purchase agreement with certain institutional purchasers. Each common unit consisted of one ordinary share, par value NIS 0.25 per share, and one common warrant to purchase one ordinary share. Each pre-funded unit consisted of one pre-funded warrant to purchase one ordinary share and one common warrant. Additionally, the Company issued warrants to purchase up to 336,000 ordinary shares, with an exercise price of $1.5625 per share, to representatives of H.C. Wainwright as compensation for its role as the placement agent in the Company’s February 2020 offering.							The Company’s follow-on public offering of 496,040 units, each consisting of one ordinary share and one common warrant to purchase one ordinary share with an exercise price of $7.5 per warrant. Each unit was sold to the public at a price of $7.50 per unit. On November 18, 2018, H.C. Wainwright exercised in full its option to purchase 231,964 ordinary shares for $7.25 per share and/or common warrants to purchase up to an additional 231,964 ordinary shares for $0.25 per warrant.
Reverse share split, description						The Company’s shareholders approved (i) a reverse share split within a range of 1:8 to 1:32, to be effective at the ratio and on a date to be determined by the Board of Directors, and (ii) amendments to the Company’s Articles of Association authorizing an increase in the Company’s authorized share capital (and corresponding authorized number of ordinary shares, proportionally adjusting such number for the reverse share split) by up to NIS 17.5 million. Following the shareholder approval, an authorized committee of the Board of Directors of the Company approved a one-for-twenty-five reverse share split of the Company’s ordinary shares, and the Company filed the Third Amended and Restated Articles of Association of the Company with the Registrar of Companies of the State of Israel to effect the reverse share split and to increase the Company’s authorized share capital after the effect of the reverse share split. The reverse share split became effective on April 1, 2019. Additionally, effective at the same time, the total number of ordinary shares the Company is authorized to issue changed from 250,000,000 shares to 60,000,000 shares, the par value per share of the ordinary shares changed to NIS 0.25 and the authorized share capital of the Company changed from NIS 2,500,000 to NIS 15,000,000. All share and per share data included in these condensed consolidated financial statements, for periods before the three months ended June 30, 2019, give retroactive effect to the reverse stock split.
Description of underwriters warrants to purchase								The Company issued and sold 1,050,372 pre-funded units at a price to the public of $7.25 per unit. Each unit containing one pre-funded warrant with an exercise price of $0.25 per share and one warrant to purchase one ordinary share with an exercise price of $7.50 per warrant. The total gross proceeds received from the November 2018 follow-on public offering, before deducting commissions, discounts and expenses, were $13.1 million (including proceeds from the exercise of 90,691 pre-funded warrants at the closing of the offering). As of December 31, 2018, additional pre-funded warrants to purchase an aggregate 562,466 ordinary shares had been exercised, for additional proceeds of $140,617. During the three months ended June 30, 2019, additional pre-funded warrants and warrants to purchase an aggregate 584,087 ordinary shares had been exercised, for additional proceeds of $107,303. As compensation for their role in the offering, the Company also issued to the Underwriters warrants to purchase up to 106,680 ordinary shares, which became immediately exercisable starting on November 20, 2018 until November 15, 2023 at $9.375 per share.
Warrants to purchase ordinary shares | shares											1,246,500
Securities Purchase Agreements [Member]
Shareholders' Equity (Textual)
Exercise price per share | $ / shares					$ 5.14
Number of warrants issued | shares		416,667			408,457											416,667
Warrants exercisable, description		Exercisable from June 12, 2019 until December 12, 2024.	Exercisable from June 5, 2019 or June 6, 2019 until June 5, 2024 or June 6, 2024.	Exercisable from June 5, 2019 or June 6, 2019 until June 5, 2024 or June 6, 2024.	Exercisable from April 5, 2019 until October 7, 2024.
Issuance of ordinary shares, shares | shares		833,334	1,464,665	1,464,665	816,914
Exercise price ordinary shares | $ / shares		$ 6.00	$ 7.50	$ 7.50	$ 5.2025
Securities Purchase Agreements [Member] | NIS [Member]
Shareholders' Equity (Textual)
Exercise price ordinary shares | ₪ / shares																₪ 0.25
Securities Purchase Agreements [Member] | Additional Warrant to Purchase [Member]
Shareholders' Equity (Textual)
Warrants exercisable, description		Exercisable from June 12, 2019 until June 10, 2024.	Exercisable from June 5, 2019 until June 5, 2024.	Exercisable from June 5, 2019 until June 5, 2024.	Exercisable from April 5, 2019 until April 3, 2024.
Issuance of ordinary shares, shares | shares		50,000	87,880	87,880	49,015
Exercise price ordinary shares | $ / shares		$ 7.50	$ 9.375	$ 9.375	$ 6.503125
Placement agent agreement [Member]
Shareholders' Equity (Textual)
Issuance of ordinary shares (in shares) | shares | shares							760,000
Sale of stock price per share | $ / shares							$ 5.75
Total gross proceeds received from the follow-on public offering | $							$ 4,370
Description of wainwright or its designees warrants to purchase							The Company also issued to H.C Wainwright and/or its designees warrants to purchase up to 45,600 ordinary shares, which are immediately exercisable starting on February 25, 2019 until February 21, 2024 at $7.1875 per share.
Kreos Capital V [Member]
Shareholders' Equity (Textual)
Warrants grant date														Dec. 31, 2015
Warrants exercisable, description														currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction.
Kreos Capital [Member]
Shareholders' Equity (Textual)
Exercise price per share | $ / shares														$ 7.5
Drawdown amount under loan agreement | $																	$ 8,000
Timwell Corporation Limited [Member]
Shareholders' Equity (Textual)
Aggregate number of ordinary shares | shares										640,000
Gross proceeds | $										$ 20,000
Fees and other related expenses | $										705
Net aggregate proceeds of after deducting fees and other related expenses | $										$ 4,300
Description of tranche consisting									The Company entered into a fee and release agreement with Canaccord Genuity LLC (“Canaccord Genuity”) requiring the Company to pay to Canaccord Genuity, in connection with a settlement, in addition to certain cash amounts, (i) $125 thousand in ordinary shares of the Company after the First Tranche Closing of the Timwell transaction and (ii) $225 thousand in ordinary shares of the Company after the closing of the Second Tranche of the Timwell transaction (or such lower amount if the Second Tranche Closing is less than $10.0 million). The price per share used for calculation of the number of ordinary shares issued by the Company to Canaccord Genuity is based on the volume weighted average price of the Company’s ordinary shares as reported on the Nasdaq Capital Market for the five consecutive trading days prior to the date of issuance. The Company is also obligated to pay $100 thousand in cash following the closing of the Third Tranche of $5.0 million (or such lower amount if the Third Tranche Closing is less than $5.0 million). Following the First Tranche Closing in May 15, 2018, the Company issued 4,715 ordinary shares to Canaccord Genuity.	The Company entered into an investment agreement with Timwell Corporation Limited, a Hong Kong corporation (“Timwell”), as amended on May 15, 2018 (the “Investment Agreement”), pursuant to which the Company agreed to issue to Timwell, in three different tranches, an aggregate of 640,000 ordinary shares in return for aggregate gross proceeds of $20 million. The closing of each tranche is subject to certain closing conditions. The closing of the first tranche (the “First Tranche Closing”) took place on May 15, 2018, upon which Timwell received 160,000 ordinary shares for an aggregate purchase price of $5,000,000, and Timwell and the Company signed a registration rights agreement in the form attached to the Investment Agreement. The net aggregate proceeds of the First Tranche Closing after deducting fees and other related expenses in the amount of approximately $705 thousands were approximately $4.3 million. The remaining investment is to occur in two tranches, including $10 million for the issuance to Timwell of 320,000 ordinary shares (the “Second Tranche”) and $5 million for the issuance to Timwell of 160,000 ordinary shares (the “Third Tranch”). The closing of the second and third tranches is subject to specified closing conditions, including, with respect to the second tranche, the signing of a license agreement and a supply agreement and the formation of the China JV (the “China JV”) based on the JV Framework Agreement, and, with respect to the third tranche, the successful production of certain ReWalk products by the China JV. The second tranche closing was initially expected to occur by July 1, 2018 and the third tranche closing was initially expected to occur by December 31, 2018 and no later than April 1, 2019.
Employee Stock Option [Member]
Shareholders' Equity (Textual)
Award vesting period, description												Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year.
Shares reserved for future issuance (in shares) | shares											1,559,751	1,559,751			12,409
Unrecognized cost of shares | $											$ 968	$ 968			$ 857,000
Expected term of shares												2 years 10 months 6 days
Restricted Stock Units (RSUs) [Member]
Shareholders' Equity (Textual)
Weighted average grant date fair value, restricted stock units (in USD per share) | $ / shares												$ 2.23	$ 4.69
Weighted average grant date fair value, options (in USD per share) | $ / shares													$ 2.98